Skip to main content
Ir a la página de inicio de la Comisión Europea (se abrirá en una nueva ventana)
español es
CORDIS - Resultados de investigaciones de la UE
CORDIS

NAO.VNS: A New Personalized Neural Stimulation Therapy For Drug-resistant Epilepsy

Objetivo

19.5M world population suffer from Drug-Resistant Epilepsy (DRE) with symptoms poorly controlled. 8M are not eligible for brain surgery. Vagus nerve stimulation is nowadays the best treatment option. But unfortunately, current solutions do not reply to the clinical need. They cannot adapt to each patient making the patient's therapeutic journey complicated and expensive.

We created NAO.VNS the next-generation implantable vagus nerve neurostimulator. We replaced metal wires by optical fibres to convert optical energy to electrical impulses rendering the device compliant with MRI & brain scans essential for disease diagnosis or treatment. Through NAO.VNS patients & physicians receive remote feedback on the direct effect & efficacy of the neural stimulation, to precisely & uniquely adapt therapy.

Through EIC funding, we will complete a clinical pilot trial & a pivotal study in the EU/US to initiate market approvals. We expect to generate €89M by 2028 selling in the EU/US.

Ámbito científico (EuroSciVoc)

Palabras clave

Programa(s)

Tema(s)

Régimen de financiación

HORIZON-EIC-ACC-BF - HORIZON EIC Accelerator Blended Finance

Ver todos los proyectos financiados en el marco de este régimen de financiación

Convocatoria de propuestas

(se abrirá en una nueva ventana) HORIZON-EIC-2022-ACCELERATOR-01

Ver todos los proyectos financiados en el marco de esta convocatoria

Coordinador

SYNERGIA MEDICAL
Aportación neta de la UEn
€ 2 499 000,00
Dirección
RUE EMILE FRANCQUI 6
1435 Mont-Saint-Guibert
Bélgica
Pyme
Sí
Región
Région wallonne Prov. Brabant Wallon Arr. Nivelles
Tipo de actividad
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Enlaces
Coste total
€ 4 471 250,00